Health · Medical Research · 1 hr ago
LG Chem plans clinical development of AI-designed cancer vaccine in 2029
At a conference in Seoul, LG Chem outlined plans to use AI in cancer treatment and drug development.
The company is building an AI model to study each patient’s cancer and predict new antigens that could prompt an immune response.
These predicted antigens would be used to develop personalized mRNA cancer vaccines.
LG Chem plans to complete preclinical work in 2027, then begin clinical development in 2029.
It also plans to use AI to identify patients most likely to benefit from treatments and to help design clinical trials using biomarkers.
The approach matters because it aims to match treatments more closely to the biology of individual cancers, but the vaccine is still in development.
LG Chem plans to begin clinical development of an AI-designed personalized mRNA cancer vaccine in 2029.
The company said it is developing an AI model to predict neoantigens that may trigger immune responses, based on the characteristics of each patient’s cancer cells.
LG Chem plans to take the vaccine through preclinical development in 2027 before moving into clinical development.
The company also plans to use AI to identify patients likely to benefit from treatment and to design clinical trials using biomarkers.
The plans were presented at the 2026 LG AI Bio Conference in Seoul, attended by about 140 people from AI and biotechnology companies.
- Who
- LG Chem.
- What
- It plans to begin clinical development of an AI-designed personalized mRNA cancer vaccine in 2029.
- When
- The plan was announced on October 20, 2026. Clinical development is planned for 2029.
- Where
- At the 2026 LG AI Bio Conference at LG Sciencepark in Gangseo District, Seoul.
- Why
- The vaccine uses AI to predict neoantigens from the characteristics of each patient’s cancer cells, with the aim of inducing an immune response.
This story does not have two clearly opposing sides.
LG Chem, LG AI Research and Flagship Pioneering held the 2026 LG AI Bio Conference in Seoul.
LG Chem plans to take its personalized mRNA cancer vaccine through preclinical development.
LG Chem plans to begin clinical development of the vaccine.
- Planned clinical development
- 2029
- Planned preclinical stage
- 2027
- Conference date
- October 20, 2026
- Conference location
- LG Sciencepark, Gangseo District, Seoul
- Conference attendance
- About 140 people from domestic and international AI and biotechnology companies
1 source
What people are saying
AI is evolving from a tool for drug development into a core engine that determines competitiveness
The competitiveness of future drug development lies in finding structurally superior drugs (Right Drug) as well as using AI to find patients who are likely to have a high treatment effect (Right Patient)
LG Chem and Flagship Pioneering are expanding cooperation in life sciences by using AI as a common engine of innovation